Literature DB >> 7945251

Microheterogeneity of cytosolic and membrane-bound hexokinase II in Morris hepatoma 3924A.

A Rempel1, P Bannasch, D Mayer.   

Abstract

Phosphorylation of glucose by hexokinase is the key step in glucose and energy metabolism of the cell. In the Morris hepatoma 3924A, hexokinase II is the predominant hexokinase isoenzyme and occurs in the cytosol as well as bound to membranes. Hexokinase II was isolated by DEAE-cellulose chromatography from both the cytosolic and the mitochondria-enriched fractions and further resolved by hydrophobic-interaction chromatography on phenyl-Sepharose into two components designated hexokinase IIa and IIb. In both the soluble and the mitochondria-enriched fractions, type IIb was the predominant form, but the IIb/IIa ratio was higher in the particulate (6-8) as compared with the cytosolic fraction (1.5-2.0). Binding of the isolated forms of the enzyme to rat liver mitochondria resulted in a 2-10-fold activation of both subtypes. Biochemical characterization showed that both subtypes are closely related to the isoenzyme commonly referred to as hexokinase II, and that the microheterogeneity was not a consequence of contamination with hexokinase I or III. Both subtypes had a molecular mass of 110 kDa, they were inhibited by Pi at concentrations higher than 5 mM, and activated by the detergent CHAPS. The two subtypes differed in electrophoretic mobility (IIa > IIb), in Km values for glucose (IIa, 0.109 mM; IIb, 0.216 mM), in Ki values for glucose 6-phosphate (IIa, 25 microM; IIb, 0.106 mM), and in Ki values for glucose 1,6-biphosphate (IIa, 12.2 microM; IIb, 5.5 microM). An artificial proteolytic cleavage as cause of the hexokinase II microheterogeneity can be excluded, since both subtypes show the same molecular mass and the ability to bind to mitochondria and phenyl-Sepharose. In addition, the relative proportions of the two subtypes did not vary markedly between several enzyme preparations. Northern-blot analysis with a hexokinase II-specific cDNA probe revealed two distinct mRNA transcripts of 5.2 and 6.3 kb in length, which offers the possibility that hexokinase II microheterogeneity is due to differential RNA transcription and/or processing.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7945251      PMCID: PMC1137586          DOI: 10.1042/bj3030269

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  45 in total

1.  Purification and properties of rat skeletal muscle hexokinase.

Authors:  M J Holroyde; I P Trayer
Journal:  FEBS Lett       Date:  1976-02-15       Impact factor: 4.124

Review 2.  Enzymology of cancer cells (second of two parts).

Authors:  G Weber
Journal:  N Engl J Med       Date:  1977-03-10       Impact factor: 91.245

3.  Isozyme studies of several enzymes of carbohydrate metabolism in human adult and fetal tissues, tumor tissues, and cell cultures.

Authors:  K D Hammond; D Balinsky
Journal:  Cancer Res       Date:  1978-05       Impact factor: 12.701

4.  RNA molecular weight determinations by gel electrophoresis under denaturing conditions, a critical reexamination.

Authors:  H Lehrach; D Diamond; J M Wozney; H Boedtker
Journal:  Biochemistry       Date:  1977-10-18       Impact factor: 3.162

5.  PH dependence of the alpha-glucose 1,6-diphosphate inhibition of hexokinase II.

Authors:  I A Rose; J V Warms
Journal:  Arch Biochem Biophys       Date:  1975-12       Impact factor: 4.013

6.  Specificity for the glucose-6-P inhibition site of hexokinase.

Authors:  I A Rose; J V Warms; D P Kosow
Journal:  Arch Biochem Biophys       Date:  1974-10       Impact factor: 4.013

7.  Purification and properties of pig-heart hexokinase.

Authors:  J S Easterby; M J O'Brien
Journal:  Eur J Biochem       Date:  1973-10-05

8.  A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors.

Authors:  A Cornish-Bowden
Journal:  Biochem J       Date:  1974-01       Impact factor: 3.857

9.  Comparison of type I hexokinases from pig heart and kinetic evaluation of the effects of inhibitors.

Authors:  D T Vowles; J S Easterby
Journal:  Biochim Biophys Acta       Date:  1979-02-09

10.  Heart hexokinase: quaternary structure changes accompanying the binding of regulatory molecules.

Authors:  J S Easterby
Journal:  Eur J Biochem       Date:  1975-10-01
View more
  6 in total

Review 1.  Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy.

Authors:  Saroj P Mathupala; Young H Ko; Peter L Pedersen
Journal:  Semin Cancer Biol       Date:  2008-12-03       Impact factor: 15.707

Review 2.  Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria.

Authors:  S P Mathupala; Y H Ko; P L Pedersen
Journal:  Oncogene       Date:  2006-08-07       Impact factor: 9.867

Review 3.  The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies.

Authors:  Saroj P Mathupala; Young H Ko; Peter L Pedersen
Journal:  Biochim Biophys Acta       Date:  2010-04-08

Review 4.  Early bioenergetic changes in hepatocarcinogenesis: preneoplastic phenotypes mimic responses to insulin and thyroid hormone.

Authors:  P Bannasch; F Klimek; D Mayer
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

Review 5.  Hexokinase binding to mitochondria: a basis for proliferative energy metabolism.

Authors:  S G Golshani-Hebroni; S P Bessman
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

6.  Mitochondrial and nuclear genes of mitochondrial components in cancer.

Authors:  E Kirches
Journal:  Curr Genomics       Date:  2009-06       Impact factor: 2.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.